Literature DB >> 10775672

Identification of matrix metalloproteinases and their tissue inhibitors type 1 and 2 in human masseter muscle.

A Singh1, Z L Nelson-Moon, G J Thomas, N P Hunt, M P Lewis.   

Abstract

Changes in masticatory muscle structure and function are either developmental, as seen in anomalies of facial form, or adaptive, as seen during procedures such as orthognathic surgery and functional-appliance orthodontic therapy. Remodelling of muscle extracellular matrix is pivotal in these processes. This turnover is mediated via members of the family of enzymes known as matrix metalloproteinases (MMP) and inhibited by the tissue inhibitors of metalloproteinases (TIMP). The aim here was to investigate the in vivo pattern of expression and distribution of MMPs and TIMPs in masseter muscle of humans with both normal and abnormal facial forms. Masseter muscle biopsies were taken from 10 patients, four with long-face syndrome and six normal controls as confirmed by cephalometry. Immunohistochemical techniques were used to show the pattern and distribution of MMPs and TIMP proteins in the muscle. Zymography of tissue extracts was used to determine the presence of MMP activity. Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to detect the presence of MMP and TIMP-2 mRNA. MMP-1 was expressed around the individual muscle fibres, especially in those fibre surfaces in contact with the interstices of the connective tissue and around blood vessels. MMP-9 staining was less intense and was expressed in the interstices of the connective tissue and around blood vessels. Zymography of protein extracts confirmed that MMP-9 activity was present. MMP-2 and MMP-3 were not expressed in the samples, although MMP-2 mRNA could be detected by RT-PCR and its activity could be detected by zymography. Intense TIMP-1 staining was present around each muscle fibre, in the interstices of the connective tissue and surrounding blood vessels; TIMP-2 mRNA could be detected in all samples. These staining patterns were seen in all biopsies examined and were irrespective of the facial form of the donor. These findings provide evidence that the mechanisms required for matrix remodelling are present in the human masseter muscle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775672     DOI: 10.1016/s0003-9969(00)00020-0

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  6 in total

1.  Matrix metalloprotease-3 and tissue inhibitor of metalloprotease-1 mRNA and protein levels are altered in response to traumatic skeletal muscle injury.

Authors:  Maria L Urso; Eric R Szelenyi; Gordon L Warren; Brian R Barnes
Journal:  Eur J Appl Physiol       Date:  2010-03-27       Impact factor: 3.078

2.  Decrease of MMP-9 activity improves soleus muscle regeneration.

Authors:  Malgorzata Zimowska; Krzysztof H Olszynski; Marta Swierczynska; Wladyslawa Streminska; Maria A Ciemerych
Journal:  Tissue Eng Part A       Date:  2012-04-20       Impact factor: 3.845

Review 3.  Structure and function of the skeletal muscle extracellular matrix.

Authors:  Allison R Gillies; Richard L Lieber
Journal:  Muscle Nerve       Date:  2011-09       Impact factor: 3.217

4.  The congenital clubfoot - immunohistological analysis of the extracellular matrix.

Authors:  Arno Kerling; Gisela Stoltenburg-Didinger; Lena Grams; Uwe Tegtbur; Hauke Horstmann; Momme Kück; Holger Mellerowicz
Journal:  Orthop Res Rev       Date:  2018-08-23

Review 5.  Matrix metalloproteinase and tissue inhibitor of metalloproteinase responses to muscle damage after eccentric exercise.

Authors:  Jooyoung Kim; Joohyung Lee
Journal:  J Exerc Rehabil       Date:  2016-08-31

6.  Regulation of extracellular matrix elements and sarcomerogenesis in response to different periods of passive stretching in the soleus muscle of rats.

Authors:  Sabrina M Peviani; Vinicius Guzzoni; Clara M Pinheiro-Dardis; Yara P da Silva; Alisson C R Fioravante; Adriana H Sagawa; Gabriel B Delfino; João L Q Durigan; Tania F Salvini
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.